Showing 3761-3770 of 8606 results for "".
- Meta-analysis: Severe Childhood Sunburns Triple Risk of cSCChttps://practicaldermatology.com/news/meta-analysis-severe-childhood-sunburns-triple-risk-of-cscc/2483566/Data from a new meta-analysis showed an association between severe sunburn history and increased risk of cutaneous squamous cell carcinoma (cSCC) across all life stages. Researchers publishing in JAMA Dermatology use
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- Low Recurrence Observed in MIS Cases With Clear Biopsy Marginshttps://practicaldermatology.com/news/low-recurrence-observed-in-mis-cases-with-clear-biopsy-margins/2483319/A new retrospective cohort study suggests that diagnostic excisional biopsy alone maya be efficacious for select cases of melanoma in situ (MIS) that are neither lentigo maligna (LM) nor acral lentiginous melanoma (ALM) subtypes.
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Psoriasis Patients Show Significant Link to Metabolic Syndrome in Indian Studyhttps://practicaldermatology.com/news/psoriasis-patients-show-significant-link-to-metabolic-syndrome-in-indian-study/2483264/A hospital-based cross-sectional study from India has found that patients with chronic plaque psoriasis show a significant association with metabolic syndrome, highlighting the importance of routine metabolic screening in dermatology practice. Published in <
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th